HUE027164T2 - Novel immunogenic epitopes for immunotherapy - Google Patents

Info

Publication number

HUE027164T2

HUE027164T2 HUE12191623A HUE12191623A HUE027164T2 HU E027164 T2 HUE027164 T2 HU E027164T2 HU E12191623 A HUE12191623 A HU E12191623A HU E12191623 A HUE12191623 A HU E12191623A HU E027164 T2 HUE027164 T2 HU E027164T2

Authority

HU

Hungary

Prior art keywords

peptide

cell

cells

cancer

vol

Prior art date

2007-07-27

Links

• Espacenet
• Global Dossier
• Discuss

• 238000009169 immunotherapy Methods 0.000 title description 19
• 230000002163 immunogen Effects 0.000 title description 6
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 382
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 257
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 168
• 239000000427 antigen Substances 0.000 claims abstract description 91
• 108091007433 antigens Proteins 0.000 claims abstract description 89
• 102000036639 antigens Human genes 0.000 claims abstract description 89
• 210000004027 cell Anatomy 0.000 claims description 179
• 201000011510 cancer Diseases 0.000 claims description 131
• 241000282414 Homo sapiens Species 0.000 claims description 88
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 83
• 108090000623 proteins and genes Proteins 0.000 claims description 78
• 230000014509 gene expression Effects 0.000 claims description 76
• 238000000034 method Methods 0.000 claims description 57
• 208000005017 glioblastoma Diseases 0.000 claims description 35
• 229920001184 polypeptide Polymers 0.000 claims description 26
• 239000013598 vector Substances 0.000 claims description 25
• 210000000612 antigen-presenting cell Anatomy 0.000 claims description 21
• 239000013604 expression vector Substances 0.000 claims description 18
• 239000003814 drug Substances 0.000 claims description 16
• 238000004519 manufacturing process Methods 0.000 claims description 16
• 108020003175 receptors Proteins 0.000 claims description 13
• 102000005962 receptors Human genes 0.000 claims description 12
• 206010038389 Renal cancer Diseases 0.000 claims description 10
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 9
• 230000004913 activation Effects 0.000 claims description 9
• 201000010982 kidney cancer Diseases 0.000 claims description 8
• 239000012634 fragment Substances 0.000 claims description 6
• 108020001507 fusion proteins Proteins 0.000 claims description 5
• 102000037865 fusion proteins Human genes 0.000 claims description 5
• 238000002955 isolation Methods 0.000 claims description 5
• 230000002147 killing effect Effects 0.000 claims description 5
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
• 230000002159 abnormal effect Effects 0.000 claims description 3
• 239000001963 growth medium Substances 0.000 claims description 3
• 239000003053 toxin Substances 0.000 claims description 3
• 231100000765 toxin Toxicity 0.000 claims description 3
• 108700012359 toxins Proteins 0.000 claims description 3
• 239000002253 acid Substances 0.000 claims 6
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
• 208000004998 Abdominal Pain Diseases 0.000 claims 1
• 241000278713 Theora Species 0.000 claims 1
• 230000009858 acid secretion Effects 0.000 claims 1
• 210000004165 myocardium Anatomy 0.000 claims 1
• 229910052759 nickel Inorganic materials 0.000 claims 1
• 210000002784 stomach Anatomy 0.000 claims 1
• 230000028993 immune response Effects 0.000 abstract description 19
• 238000011282 treatment Methods 0.000 abstract description 18
• 125000003275 alpha amino acid group Chemical group 0.000 abstract description 14
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
• 201000010099 disease Diseases 0.000 abstract description 9
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 66
• 102100037362 Fibronectin Human genes 0.000 description 63
• 108010067306 Fibronectins Proteins 0.000 description 63
• 108060006698 EGF receptor Proteins 0.000 description 57
• 102000001301 EGF receptor Human genes 0.000 description 55
• 210000001519 tissue Anatomy 0.000 description 47
• 238000000338 in vitro Methods 0.000 description 46
• 102000004169 proteins and genes Human genes 0.000 description 41
• 235000018102 proteins Nutrition 0.000 description 39
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 38
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 38
• 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 37
• 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 36
• 210000004443 dendritic cell Anatomy 0.000 description 36
• 230000027455 binding Effects 0.000 description 33
• 108020004414 DNA Proteins 0.000 description 32
• 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 26
• 238000002255 vaccination Methods 0.000 description 25
• 238000004458 analytical method Methods 0.000 description 24
• 108091054437 MHC class I family Proteins 0.000 description 23
• 210000004698 lymphocyte Anatomy 0.000 description 22
• 238000002965 ELISA Methods 0.000 description 21
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 21
• 230000000638 stimulation Effects 0.000 description 21
• 206010009944 Colon cancer Diseases 0.000 description 20
• 108091054438 MHC class II family Proteins 0.000 description 20
• 210000004881 tumor cell Anatomy 0.000 description 19
• 229960005486 vaccine Drugs 0.000 description 19
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 18
• 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 18
• 230000005847 immunogenicity Effects 0.000 description 18
• 230000001404 mediated effect Effects 0.000 description 18
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
• 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 17
• 239000002671 adjuvant Substances 0.000 description 17
• 230000000694 effects Effects 0.000 description 17
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 17
• 102000039446 nucleic acids Human genes 0.000 description 17
• 108020004707 nucleic acids Proteins 0.000 description 17
• 150000007523 nucleic acids Chemical class 0.000 description 17
• 230000004044 response Effects 0.000 description 17
• -1 superoxide anions Chemical class 0.000 description 17
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 16
• 102000043129 MHC class I family Human genes 0.000 description 16
• 230000000259 anti-tumor effect Effects 0.000 description 16
• 230000006870 function Effects 0.000 description 16
• 230000006698 induction Effects 0.000 description 16
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 15
• 101001108219 Homo sapiens NADPH oxidase 1 Proteins 0.000 description 15
• 102100021873 NADPH oxidase 1 Human genes 0.000 description 15
• 239000003446 ligand Substances 0.000 description 15
• 239000000203 mixture Substances 0.000 description 15
• 102100021176 ATP-sensitive inward rectifier potassium channel 10 Human genes 0.000 description 14
• 241000699670 Mus sp. Species 0.000 description 14
• 230000005867 T cell response Effects 0.000 description 14
• 238000002560 therapeutic procedure Methods 0.000 description 14
• 208000003174 Brain Neoplasms Diseases 0.000 description 13
• 101000885387 Homo sapiens Serine/threonine-protein kinase DCLK2 Proteins 0.000 description 13
• 108010002350 Interleukin-2 Proteins 0.000 description 13
• 102000000588 Interleukin-2 Human genes 0.000 description 13
• 102100039775 Serine/threonine-protein kinase DCLK2 Human genes 0.000 description 13
• 230000001419 dependent effect Effects 0.000 description 13
• 238000011161 development Methods 0.000 description 13
• 230000018109 developmental process Effects 0.000 description 13
• 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 13
• 239000002609 medium Substances 0.000 description 13
• 230000004048 modification Effects 0.000 description 13
• 238000012986 modification Methods 0.000 description 13
• 230000001105 regulatory effect Effects 0.000 description 13
• 239000000523 sample Substances 0.000 description 13
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 12
• 230000003321 amplification Effects 0.000 description 12
• 210000001072 colon Anatomy 0.000 description 12
• 238000003199 nucleic acid amplification method Methods 0.000 description 12
• 239000012071 phase Substances 0.000 description 12
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 11
• 102100040683 Fermitin family homolog 1 Human genes 0.000 description 11
• 108091008874 T cell receptors Proteins 0.000 description 11
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 206010017758 gastric cancer Diseases 0.000 description 11
• 230000012010 growth Effects 0.000 description 11
• 210000002443 helper t lymphocyte Anatomy 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 210000004072 lung Anatomy 0.000 description 11
• 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 10
• 108010075704 HLA-A Antigens Proteins 0.000 description 10
• 102000043131 MHC class II family Human genes 0.000 description 10
• 208000006265 Renal cell carcinoma Diseases 0.000 description 10
• 230000033115 angiogenesis Effects 0.000 description 10
• 230000006907 apoptotic process Effects 0.000 description 10
• 239000011324 bead Substances 0.000 description 10
• 210000000987 immune system Anatomy 0.000 description 10
• 230000003993 interaction Effects 0.000 description 10
• 201000005202 lung cancer Diseases 0.000 description 10
• 208000020816 lung neoplasm Diseases 0.000 description 10
• 210000004498 neuroglial cell Anatomy 0.000 description 10
• 230000035755 proliferation Effects 0.000 description 10
• 230000001225 therapeutic effect Effects 0.000 description 10
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
• 102000004190 Enzymes Human genes 0.000 description 9
• 108090000790 Enzymes Proteins 0.000 description 9
• 101000614696 Homo sapiens ATP-sensitive inward rectifier potassium channel 10 Proteins 0.000 description 9
• 101000892670 Homo sapiens Fermitin family homolog 1 Proteins 0.000 description 9
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
• 210000004556 brain Anatomy 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 238000009472 formulation Methods 0.000 description 9
• 108020004999 messenger RNA Proteins 0.000 description 9
• 230000001394 metastastic effect Effects 0.000 description 9
• 206010061289 metastatic neoplasm Diseases 0.000 description 9
• 210000004688 microtubule Anatomy 0.000 description 9
• 230000002018 overexpression Effects 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 230000037452 priming Effects 0.000 description 9
• 230000004083 survival effect Effects 0.000 description 9
• 238000012360 testing method Methods 0.000 description 9
• 108700028369 Alleles Proteins 0.000 description 8
• 206010006187 Breast cancer Diseases 0.000 description 8
• 101000720704 Homo sapiens Neuronal migration protein doublecortin Proteins 0.000 description 8
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 8
• 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 8
• 102000029749 Microtubule Human genes 0.000 description 8
• 108091022875 Microtubule Proteins 0.000 description 8
• 102100025929 Neuronal migration protein doublecortin Human genes 0.000 description 8
• 108010029485 Protein Isoforms Proteins 0.000 description 8
• 102000001708 Protein Isoforms Human genes 0.000 description 8
• 208000005718 Stomach Neoplasms Diseases 0.000 description 8
• 125000000539 amino acid group Chemical group 0.000 description 8
• 238000013459 approach Methods 0.000 description 8
• 230000002496 gastric effect Effects 0.000 description 8
• 229960002584 gefitinib Drugs 0.000 description 8
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 8
• 210000000265 leukocyte Anatomy 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 201000011549 stomach cancer Diseases 0.000 description 8
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
• 208000026310 Breast neoplasm Diseases 0.000 description 7
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 7
• 206010018338 Glioma Diseases 0.000 description 7
• 108010058597 HLA-DR Antigens Proteins 0.000 description 7
• 102000006354 HLA-DR Antigens Human genes 0.000 description 7
• 229940124672 IMA901 Drugs 0.000 description 7
• 108010010995 MART-1 Antigen Proteins 0.000 description 7
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 7
• 229940024606 amino acid Drugs 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 229940022399 cancer vaccine Drugs 0.000 description 7
• 238000009566 cancer vaccine Methods 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 238000010494 dissociation reaction Methods 0.000 description 7
• 230000005593 dissociations Effects 0.000 description 7
• 239000002158 endotoxin Substances 0.000 description 7
• 229940116977 epidermal growth factor Drugs 0.000 description 7
• 238000010195 expression analysis Methods 0.000 description 7
• 230000001900 immune effect Effects 0.000 description 7
• 230000001939 inductive effect Effects 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 102000006495 integrins Human genes 0.000 description 7
• 108010044426 integrins Proteins 0.000 description 7
• 229920006008 lipopolysaccharide Polymers 0.000 description 7
• 201000005296 lung carcinoma Diseases 0.000 description 7
• 238000013508 migration Methods 0.000 description 7
• 230000035772 mutation Effects 0.000 description 7
• 208000008443 pancreatic carcinoma Diseases 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• 238000011160 research Methods 0.000 description 7
• 238000000926 separation method Methods 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• 239000002904 solvent Substances 0.000 description 7
• 238000010186 staining Methods 0.000 description 7
• 238000007920 subcutaneous administration Methods 0.000 description 7
• MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 6
• 208000003200 Adenoma Diseases 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• 201000009030 Carcinoma Diseases 0.000 description 6
• 230000004544 DNA amplification Effects 0.000 description 6
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 6
• 108010074781 Kcnj10 (channel) Proteins 0.000 description 6
• 206010027476 Metastases Diseases 0.000 description 6
• 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 6
• 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 6
• 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 6
• 102100033117 Toll-like receptor 9 Human genes 0.000 description 6
• 235000001014 amino acid Nutrition 0.000 description 6
• 150000001413 amino acids Chemical class 0.000 description 6
• 210000001130 astrocyte Anatomy 0.000 description 6
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 239000002299 complementary DNA Substances 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 230000003828 downregulation Effects 0.000 description 6
• 230000002518 glial effect Effects 0.000 description 6
• 238000002372 labelling Methods 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 6
• 238000004949 mass spectrometry Methods 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 230000009401 metastasis Effects 0.000 description 6
• 238000002493 microarray Methods 0.000 description 6
• 239000004005 microsphere Substances 0.000 description 6
• 230000005012 migration Effects 0.000 description 6
• 210000001616 monocyte Anatomy 0.000 description 6
• 201000002528 pancreatic cancer Diseases 0.000 description 6
• 239000013612 plasmid Substances 0.000 description 6
• 102000040430 polynucleotide Human genes 0.000 description 6
• 108091033319 polynucleotide Proteins 0.000 description 6
• 239000002157 polynucleotide Substances 0.000 description 6
• 238000012552 review Methods 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 230000009466 transformation Effects 0.000 description 6
• 229940122450 Altered peptide ligand Drugs 0.000 description 5
• 101800003838 Epidermal growth factor Proteins 0.000 description 5
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 5
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 5
• 208000034607 Kindler epidermolysis bullosa Diseases 0.000 description 5
• 201000004290 Kindler syndrome Diseases 0.000 description 5
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
• 108091034117 Oligonucleotide Proteins 0.000 description 5
• 108091000080 Phosphotransferase Proteins 0.000 description 5
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 5
• 108020004459 Small interfering RNA Proteins 0.000 description 5
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 5
• 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 5
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 208000029742 colonic neoplasm Diseases 0.000 description 5
• 150000001875 compounds Chemical class 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 210000002950 fibroblast Anatomy 0.000 description 5
• 238000013467 fragmentation Methods 0.000 description 5
• 238000006062 fragmentation reaction Methods 0.000 description 5
• 230000004927 fusion Effects 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 5
• 208000029824 high grade glioma Diseases 0.000 description 5
• 238000011068 loading method Methods 0.000 description 5
• 239000012931 lyophilized formulation Substances 0.000 description 5
• 230000036210 malignancy Effects 0.000 description 5
• 201000011614 malignant glioma Diseases 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 239000013642 negative control Substances 0.000 description 5
• 102000020233 phosphotransferase Human genes 0.000 description 5
• 229910052700 potassium Inorganic materials 0.000 description 5
• 239000011591 potassium Substances 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 238000012546 transfer Methods 0.000 description 5
• 230000004614 tumor growth Effects 0.000 description 5
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
• 239000005695 Ammonium acetate Substances 0.000 description 4
• 241000282461 Canis lupus Species 0.000 description 4
• 108010022172 Chitinases Proteins 0.000 description 4
• 102000012286 Chitinases Human genes 0.000 description 4
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 206010013457 Dissociation Diseases 0.000 description 4
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
• 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 4
• 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
• 108090000978 Interleukin-4 Proteins 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• 239000004472 Lysine Substances 0.000 description 4
• 102000018697 Membrane Proteins Human genes 0.000 description 4
• 108010052285 Membrane Proteins Proteins 0.000 description 4
• 206010027480 Metastatic malignant melanoma Diseases 0.000 description 4
• 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 4
• 206010033128 Ovarian cancer Diseases 0.000 description 4
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 102100035703 Prostatic acid phosphatase Human genes 0.000 description 4
• 102000001253 Protein Kinase Human genes 0.000 description 4
• 108091030071 RNAI Proteins 0.000 description 4
• 230000024932 T cell mediated immunity Effects 0.000 description 4
• 208000024770 Thyroid neoplasm Diseases 0.000 description 4
• 102000002689 Toll-like receptor Human genes 0.000 description 4
• 108020000411 Toll-like receptor Proteins 0.000 description 4
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 208000009956 adenocarcinoma Diseases 0.000 description 4
• 235000019257 ammonium acetate Nutrition 0.000 description 4
• 229940043376 ammonium acetate Drugs 0.000 description 4
• 230000000890 antigenic effect Effects 0.000 description 4
• 210000003050 axon Anatomy 0.000 description 4
• 210000005013 brain tissue Anatomy 0.000 description 4
• 230000003139 buffering effect Effects 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 210000000349 chromosome Anatomy 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 230000009260 cross reactivity Effects 0.000 description 4
• 235000018417 cysteine Nutrition 0.000 description 4
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
• 210000001787 dendrite Anatomy 0.000 description 4
• 208000018459 dissociative disease Diseases 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 210000001035 gastrointestinal tract Anatomy 0.000 description 4
• 238000011223 gene expression profiling Methods 0.000 description 4
• 230000009368 gene silencing by RNA Effects 0.000 description 4
• 229930195712 glutamate Natural products 0.000 description 4
• 230000036039 immunity Effects 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 108010028930 invariant chain Proteins 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 201000001441 melanoma Diseases 0.000 description 4
• 208000021039 metastatic melanoma Diseases 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 108010043671 prostatic acid phosphatase Proteins 0.000 description 4
• 108060006633 protein kinase Proteins 0.000 description 4
• 230000036390 resting membrane potential Effects 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 230000003827 upregulation Effects 0.000 description 4
• 238000010200 validation analysis Methods 0.000 description 4
• 239000003643 water by type Substances 0.000 description 4
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
• 206010001233 Adenoma benign Diseases 0.000 description 3
• 102000012002 Aquaporin 4 Human genes 0.000 description 3
• 108010036280 Aquaporin 4 Proteins 0.000 description 3
• 108010078791 Carrier Proteins Proteins 0.000 description 3
• 108091006146 Channels Proteins 0.000 description 3
• 102100038731 Chitinase-3-like protein 2 Human genes 0.000 description 3
• 108050006400 Cyclin Proteins 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 102100035428 Formiminotransferase N-terminal subdomain-containing protein Human genes 0.000 description 3
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 108090000288 Glycoproteins Proteins 0.000 description 3
• 206010019663 Hepatic failure Diseases 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 101000883325 Homo sapiens Chitinase-3-like protein 2 Proteins 0.000 description 3
• 101000877728 Homo sapiens Formiminotransferase N-terminal subdomain-containing protein Proteins 0.000 description 3
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
• 229940124673 IMA910 Drugs 0.000 description 3
• 108010002586 Interleukin-7 Proteins 0.000 description 3
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
• 108700025695 Suppressor Genes Proteins 0.000 description 3
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
• 102100040247 Tumor necrosis factor Human genes 0.000 description 3
• 229930003316 Vitamin D Natural products 0.000 description 3
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 230000005875 antibody response Effects 0.000 description 3
• 230000030741 antigen processing and presentation Effects 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 230000003140 astrocytic effect Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 231100000504 carcinogenesis Toxicity 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 230000012292 cell migration Effects 0.000 description 3
• 230000036755 cellular response Effects 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 230000001054 cortical effect Effects 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 210000002744 extracellular matrix Anatomy 0.000 description 3
• 239000011521 glass Substances 0.000 description 3
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
• 229910052737 gold Inorganic materials 0.000 description 3
• 239000010931 gold Substances 0.000 description 3
• 201000010536 head and neck cancer Diseases 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 239000000568 immunological adjuvant Substances 0.000 description 3
• 230000010354 integration Effects 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 208000007903 liver failure Diseases 0.000 description 3
• 231100000835 liver failure Toxicity 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 3
• 210000000653 nervous system Anatomy 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 210000002307 prostate Anatomy 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 230000000306 recurrent effect Effects 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 229960000714 sipuleucel-t Drugs 0.000 description 3
• CBHOWTTXCQAOID-UHFFFAOYSA-L sodium ethane formaldehyde mercury(2+) molecular iodine 2-sulfidobenzoate Chemical class [Na+].[Hg++].C[CH2-].II.C=O.[O-]C(=O)c1ccccc1[S-] CBHOWTTXCQAOID-UHFFFAOYSA-L 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 230000003068 static effect Effects 0.000 description 3
• 229960005322 streptomycin Drugs 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 201000002510 thyroid cancer Diseases 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• 239000012646 vaccine adjuvant Substances 0.000 description 3
• 229940124931 vaccine adjuvant Drugs 0.000 description 3
• 235000019166 vitamin D Nutrition 0.000 description 3
• 239000011710 vitamin D Substances 0.000 description 3
• 150000003710 vitamin D derivatives Chemical class 0.000 description 3
• 229940046008 vitamin d Drugs 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 2
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
• WEYNBWVKOYCCQT-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)NC1=CC=C(C)C(Cl)=C1 WEYNBWVKOYCCQT-UHFFFAOYSA-N 0.000 description 2
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
• 101710137115 Adenylyl cyclase-associated protein 1 Proteins 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 101800002812 Anastellin Proteins 0.000 description 2
• 102400001212 Anastellin Human genes 0.000 description 2
• 102000004550 Angiostatic Proteins Human genes 0.000 description 2
• 108010017551 Angiostatic Proteins Proteins 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 108060000903 Beta-catenin Proteins 0.000 description 2
• 102000015735 Beta-catenin Human genes 0.000 description 2
• 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 2
• 206010052346 Brain contusion Diseases 0.000 description 2
• 210000003359 CD4-positive helper T lymphocyte Anatomy 0.000 description 2
• 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 2
• 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 2
• 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 2
• 241001227713 Chiron Species 0.000 description 2
• 206010052358 Colorectal cancer metastatic Diseases 0.000 description 2
• 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 2
• 102000003915 DNA Topoisomerases Human genes 0.000 description 2
• 108090000323 DNA Topoisomerases Proteins 0.000 description 2
• 230000004543 DNA replication Effects 0.000 description 2
• 206010012434 Dermatitis allergic Diseases 0.000 description 2
• QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
• 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
• 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 102100021860 Endothelial cell-specific molecule 1 Human genes 0.000 description 2
• 101710153170 Endothelial cell-specific molecule 1 Proteins 0.000 description 2
• 229910052693 Europium Inorganic materials 0.000 description 2
• 101710108802 Fermitin family homolog 1 Proteins 0.000 description 2
• 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
• 102000016359 Fibronectins Human genes 0.000 description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
• 102400001301 Gasdermin-B, C-terminal Human genes 0.000 description 2
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
• 206010064571 Gene mutation Diseases 0.000 description 2
• 229930182566 Gentamicin Natural products 0.000 description 2
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
• 102000008214 Glutamate decarboxylase Human genes 0.000 description 2
• 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 102000009465 Growth Factor Receptors Human genes 0.000 description 2
• 108010009202 Growth Factor Receptors Proteins 0.000 description 2
• 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 description 2
• 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
• 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
• 108010062347 HLA-DQ Antigens Proteins 0.000 description 2
• 108010046732 HLA-DR4 Antigen Proteins 0.000 description 2
• 108010016996 HLA-DRB5 Chains Proteins 0.000 description 2
• 241000589989 Helicobacter Species 0.000 description 2
• 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 2
• 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
• 101000952113 Homo sapiens Probable ATP-dependent RNA helicase DDX5 Proteins 0.000 description 2
• 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
• 101000854908 Homo sapiens WD repeat-containing protein 11 Proteins 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
• 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• 108010009983 Inwardly Rectifying Potassium Channels Proteins 0.000 description 2
• 102000009855 Inwardly Rectifying Potassium Channels Human genes 0.000 description 2
• 102100033439 Janus kinase and microtubule-interacting protein 2 Human genes 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 108700005092 MHC Class II Genes Proteins 0.000 description 2
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
• 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
• 206010027202 Meningitis bacterial Diseases 0.000 description 2
• AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
• 102000004019 NADPH Oxidase 1 Human genes 0.000 description 2
• 108090000424 NADPH Oxidase 1 Proteins 0.000 description 2
• 101150036847 NOX1 gene Proteins 0.000 description 2
• 101150031836 NRCAM gene Proteins 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
• 102000004316 Oxidoreductases Human genes 0.000 description 2
• 108090000854 Oxidoreductases Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 102100039277 Pleiotrophin Human genes 0.000 description 2
• 239000004793 Polystyrene Substances 0.000 description 2
• NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
• 102100037434 Probable ATP-dependent RNA helicase DDX5 Human genes 0.000 description 2
• 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
• 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
• 108091008611 Protein Kinase B Proteins 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
• 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
• 239000013614 RNA sample Substances 0.000 description 2
• 102100038823 RNA-binding protein 45 Human genes 0.000 description 2
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
• 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 2
• 108010017842 Telomerase Proteins 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 206010064390 Tumour invasion Diseases 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 102100020705 WD repeat-containing protein 11 Human genes 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 230000001133 acceleration Effects 0.000 description 2
• 159000000021 acetate salts Chemical class 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• 125000003368 amide group Chemical group 0.000 description 2
• 230000002491 angiogenic effect Effects 0.000 description 2
• RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000003466 anti-cipated effect Effects 0.000 description 2
• 230000002001 anti-metastasis Effects 0.000 description 2
• 239000012062 aqueous buffer Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
• 238000003491 array Methods 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 201000009904 bacterial meningitis Diseases 0.000 description 2
• 108700041737 bcl-2 Genes Proteins 0.000 description 2
• 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
• 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
• 229960000397 bevacizumab Drugs 0.000 description 2
• 230000009516 brain contusion Effects 0.000 description 2
• 201000008274 breast adenocarcinoma Diseases 0.000 description 2
• 239000003560 cancer drug Substances 0.000 description 2
• 230000005907 cancer growth Effects 0.000 description 2
• 230000021235 carbamoylation Effects 0.000 description 2
• 230000021164 cell adhesion Effects 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 238000002659 cell therapy Methods 0.000 description 2
• 230000010307 cell transformation Effects 0.000 description 2
• 230000005890 cell-mediated cytotoxicity Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 238000011342 chemoimmunotherapy Methods 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 150000003841 chloride salts Chemical class 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 201000010989 colorectal carcinoma Diseases 0.000 description 2
• 210000001608 connective tissue cell Anatomy 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000003210 demyelinating effect Effects 0.000 description 2
• 238000011033 desalting Methods 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 208000018554 digestive system carcinoma Diseases 0.000 description 2
• 239000013024 dilution buffer Substances 0.000 description 2
• 230000003292 diminished effect Effects 0.000 description 2
• OQALFHMKVSJFRR-UHFFFAOYSA-N dityrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C(C=2C(=CC=C(CC(N)C(O)=O)C=2)O)=C1 OQALFHMKVSJFRR-UHFFFAOYSA-N 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 229940121647 egfr inhibitor Drugs 0.000 description 2
• 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 230000035161 fibroblast apoptotic process Effects 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 229960002949 fluorouracil Drugs 0.000 description 2
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
• 235000008191 folinic acid Nutrition 0.000 description 2
• 239000011672 folinic acid Substances 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 208000010749 gastric carcinoma Diseases 0.000 description 2
• 230000030279 gene silencing Effects 0.000 description 2
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 229920001519 homopolymer Polymers 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 102000054350 human CHI3L1 Human genes 0.000 description 2
• 125000001165 hydrophobic group Chemical group 0.000 description 2
• 238000003384 imaging method Methods 0.000 description 2
• DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000002998 immunogenetic effect Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 230000002055 immunohistochemical effect Effects 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 238000010874 in vitro model Methods 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
• 229960004768 irinotecan Drugs 0.000 description 2
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 229960001691 leucovorin Drugs 0.000 description 2
• 125000005647 linker group Chemical group 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 238000002514 liquid chromatography mass spectrum Methods 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 230000004777 loss-of-function mutation Effects 0.000 description 2
• 210000005265 lung cell Anatomy 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 239000011859 microparticle Substances 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000009448 modified atmosphere packaging Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 230000004899 motility Effects 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 229940035036 multi-peptide vaccine Drugs 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 229960002566 papillomavirus vaccine Drugs 0.000 description 2
• 238000010647 peptide synthesis reaction Methods 0.000 description 2
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
• 230000002688 persistence Effects 0.000 description 2
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
• OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 108010053725 prolylvaline Proteins 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 230000009145 protein modification Effects 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• 229940034080 provenge Drugs 0.000 description 2
• 239000003642 reactive oxygen metabolite Substances 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 210000003289 regulatory T cell Anatomy 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 229950010550 resiquimod Drugs 0.000 description 2
• BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
• 230000000284 resting effect Effects 0.000 description 2
• 230000001177 retroviral effect Effects 0.000 description 2
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 235000020046 sherry Nutrition 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 230000022379 skeletal muscle tissue development Effects 0.000 description 2
• 235000020183 skimmed milk Nutrition 0.000 description 2
• 229940054269 sodium pyruvate Drugs 0.000 description 2
• 238000010532 solid phase synthesis reaction Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 201000000498 stomach carcinoma Diseases 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 108010060175 trypsinogen activation peptide Proteins 0.000 description 2
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• 238000012795 verification Methods 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
• FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
• GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
• DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical class CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
• PVWMAOPFDINGAY-UHFFFAOYSA-N 2-(3-methylbutanoyl)indene-1,3-dione Chemical compound C1=CC=C2C(=O)C(C(=O)CC(C)C)C(=O)C2=C1 PVWMAOPFDINGAY-UHFFFAOYSA-N 0.000 description 1
• KFDPCYZHENQOBV-UHFFFAOYSA-N 2-(bromomethyl)-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1CBr KFDPCYZHENQOBV-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• VUCNQOPCYRJCGQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]acetic acid Chemical class OCC1=CC=C(OCC(O)=O)C=C1 VUCNQOPCYRJCGQ-UHFFFAOYSA-N 0.000 description 1
• IOJUJUOXKXMJNF-UHFFFAOYSA-N 2-acetyloxybenzoic acid [3-(nitrooxymethyl)phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1 IOJUJUOXKXMJNF-UHFFFAOYSA-N 0.000 description 1
• IZQAUUVBKYXMET-UHFFFAOYSA-N 2-bromoethanamine Chemical compound NCCBr IZQAUUVBKYXMET-UHFFFAOYSA-N 0.000 description 1
• JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
• APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
• MWOOKDULMBMMPN-UHFFFAOYSA-N 3-(2-ethyl-1,2-oxazol-2-ium-5-yl)benzenesulfonate Chemical compound O1[N+](CC)=CC=C1C1=CC=CC(S([O-])(=O)=O)=C1 MWOOKDULMBMMPN-UHFFFAOYSA-N 0.000 description 1
• LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
• WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
• XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
• VBVWRSJFCYCVMK-ROCTVOAFSA-N 5-[(3aR,6S,6aS)-3-hydroxy-2-oxo-3a,4,6,6a-tetrahydro-1H-thieno[3,4-d]imidazol-6-yl]-2-(2,5-dioxopyrrolidin-1-yl)-2-sulfopentanoic acid Chemical compound ON1[C@H]2CS[C@@H](CCCC(C(O)=O)(N3C(CCC3=O)=O)S(=O)(=O)O)[C@H]2NC1=O VBVWRSJFCYCVMK-ROCTVOAFSA-N 0.000 description 1
• TWQHGBJNKVFWIU-UHFFFAOYSA-N 8-[4-(4-quinolin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=C3C=CC=CC3=CC=2)C(=O)CC21CCCC2 TWQHGBJNKVFWIU-UHFFFAOYSA-N 0.000 description 1
• 101710122999 ATP-sensitive inward rectifier potassium channel 10 Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 208000007788 Acute Liver Failure Diseases 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• 206010001497 Agitation Diseases 0.000 description 1
• IKKVASZHTMKJIR-ZKWXMUAHSA-N Ala-Asp-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IKKVASZHTMKJIR-ZKWXMUAHSA-N 0.000 description 1
• SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 1
• YHKANGMVQWRMAP-DCAQKATOSA-N Ala-Leu-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YHKANGMVQWRMAP-DCAQKATOSA-N 0.000 description 1
• NOGFDULFCFXBHB-CIUDSAMLSA-N Ala-Leu-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)O)N NOGFDULFCFXBHB-CIUDSAMLSA-N 0.000 description 1
• VHVVPYOJIIQCKS-QEJZJMRPSA-N Ala-Leu-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VHVVPYOJIIQCKS-QEJZJMRPSA-N 0.000 description 1
• SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 1
• MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
• 108050008424 Alpha carbonic anhydrase domains Proteins 0.000 description 1
• 102000000086 Alpha carbonic anhydrase domains Human genes 0.000 description 1
• 206010073128 Anaplastic oligodendroglioma Diseases 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 102000010637 Aquaporins Human genes 0.000 description 1
• 108010063290 Aquaporins Proteins 0.000 description 1
• 241000272478 Aquila Species 0.000 description 1
• AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
• FXGMURPOWCKNAZ-JYJNAYRXSA-N Arg-Val-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FXGMURPOWCKNAZ-JYJNAYRXSA-N 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• NLCDVZJDEXIDDL-BIIVOSGPSA-N Asn-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O NLCDVZJDEXIDDL-BIIVOSGPSA-N 0.000 description 1
• QHBMKQWOIYJYMI-BYULHYEWSA-N Asn-Asn-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QHBMKQWOIYJYMI-BYULHYEWSA-N 0.000 description 1
• OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 description 1
• HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 1
• JLNFZLNDHONLND-GARJFASQSA-N Asn-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N JLNFZLNDHONLND-GARJFASQSA-N 0.000 description 1
• YUOXLJYVSZYPBJ-CIUDSAMLSA-N Asn-Pro-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O YUOXLJYVSZYPBJ-CIUDSAMLSA-N 0.000 description 1
• IDUUACUJKUXKKD-VEVYYDQMSA-N Asn-Pro-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O IDUUACUJKUXKKD-VEVYYDQMSA-N 0.000 description 1
• SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
• MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 1
• MYRLSKYSMXNLLA-LAEOZQHASA-N Asn-Val-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MYRLSKYSMXNLLA-LAEOZQHASA-N 0.000 description 1
• WQAOZCVOOYUWKG-LSJOCFKGSA-N Asn-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC(=O)N)N WQAOZCVOOYUWKG-LSJOCFKGSA-N 0.000 description 1
• SLHOOKXYTYAJGQ-XVYDVKMFSA-N Asp-Ala-His Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 SLHOOKXYTYAJGQ-XVYDVKMFSA-N 0.000 description 1
• VILLWIDTHYPSLC-PEFMBERDSA-N Asp-Glu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VILLWIDTHYPSLC-PEFMBERDSA-N 0.000 description 1
• SPWXXPFDTMYTRI-IUKAMOBKSA-N Asp-Ile-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SPWXXPFDTMYTRI-IUKAMOBKSA-N 0.000 description 1
• PAYPSKIBMDHZPI-CIUDSAMLSA-N Asp-Leu-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PAYPSKIBMDHZPI-CIUDSAMLSA-N 0.000 description 1
• QJHOOKBAHRJPPX-QWRGUYRKSA-N Asp-Phe-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 QJHOOKBAHRJPPX-QWRGUYRKSA-N 0.000 description 1
• AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• BXTVQNYQYUTQAZ-UHFFFAOYSA-N BNPS-skatole Chemical compound N=1C2=CC=CC=C2C(C)(Br)C=1SC1=CC=CC=C1[N+]([O-])=O BXTVQNYQYUTQAZ-UHFFFAOYSA-N 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 108020000946 Bacterial DNA Proteins 0.000 description 1
• 108020004513 Bacterial RNA Proteins 0.000 description 1
• 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
• 206010004433 Benign ovarian tumour Diseases 0.000 description 1
• 229920002498 Beta-glucan Polymers 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
• 206010048962 Brain oedema Diseases 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
• 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
• 101150071146 COX2 gene Proteins 0.000 description 1
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 101710190849 Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 241000722731 Carex Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 108091060290 Chromatid Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 241000723655 Cowpea mosaic virus Species 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• OTXLNICGSXPGQF-KBIXCLLPSA-N Cys-Ile-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTXLNICGSXPGQF-KBIXCLLPSA-N 0.000 description 1
• 206010067276 Cytotoxic oedema Diseases 0.000 description 1
• YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
• 108010090461 DFG peptide Proteins 0.000 description 1
• 102000007528 DNA Polymerase III Human genes 0.000 description 1
• 108010071146 DNA Polymerase III Proteins 0.000 description 1
• 108010041986 DNA Vaccines Proteins 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 238000000018 DNA microarray Methods 0.000 description 1
• 229940021995 DNA vaccine Drugs 0.000 description 1
• 102210012665 DRB1*03 Human genes 0.000 description 1
• 102210012675 DRB1*15 Human genes 0.000 description 1
• 101150034979 DRB3 gene Proteins 0.000 description 1
• 101150082328 DRB5 gene Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 description 1
• 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
• 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 241001295925 Gegenes Species 0.000 description 1
• JZJGEKDPWVJOLD-QEWYBTABSA-N Glu-Phe-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JZJGEKDPWVJOLD-QEWYBTABSA-N 0.000 description 1
• 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• MZZSCEANQDPJER-ONGXEEELSA-N Gly-Ala-Phe Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MZZSCEANQDPJER-ONGXEEELSA-N 0.000 description 1
• JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
• MHHUEAIBJZWDBH-YUMQZZPRSA-N Gly-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CN MHHUEAIBJZWDBH-YUMQZZPRSA-N 0.000 description 1
• VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
• CVFOYJJOZYYEPE-KBPBESRZSA-N Gly-Lys-Tyr Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CVFOYJJOZYYEPE-KBPBESRZSA-N 0.000 description 1
• 101150009006 HIS3 gene Proteins 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 208000037564 High-grade astrocytoma Diseases 0.000 description 1
• ZSKJIISDJXJQPV-BZSNNMDCSA-N His-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 ZSKJIISDJXJQPV-BZSNNMDCSA-N 0.000 description 1
• ULRFSEJGSHYLQI-YESZJQIVSA-N His-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC3=CN=CN3)N)C(=O)O ULRFSEJGSHYLQI-YESZJQIVSA-N 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
• 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
• 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
• 101000997838 Homo sapiens Janus kinase and microtubule-interacting protein 2 Proteins 0.000 description 1
• 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
• 101000693728 Homo sapiens S-acyl fatty acid synthase thioesterase, medium chain Proteins 0.000 description 1
• 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
• 241000701806 Human papillomavirus Species 0.000 description 1
• IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 1
• LPXHYGGZJOCAFR-MNXVOIDGSA-N Ile-Glu-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N LPXHYGGZJOCAFR-MNXVOIDGSA-N 0.000 description 1
• VNDQNDYEPSXHLU-JUKXBJQTSA-N Ile-His-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N VNDQNDYEPSXHLU-JUKXBJQTSA-N 0.000 description 1
• KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 1
• FZWVCYCYWCLQDH-NHCYSSNCSA-N Ile-Leu-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N FZWVCYCYWCLQDH-NHCYSSNCSA-N 0.000 description 1
• ADDYYRVQQZFIMW-MNXVOIDGSA-N Ile-Lys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ADDYYRVQQZFIMW-MNXVOIDGSA-N 0.000 description 1
• UDBPXJNOEWDBDF-XUXIUFHCSA-N Ile-Lys-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)O)N UDBPXJNOEWDBDF-XUXIUFHCSA-N 0.000 description 1
• BCISUQVFDGYZBO-QSFUFRPTSA-N Ile-Val-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O BCISUQVFDGYZBO-QSFUFRPTSA-N 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
• 101710204361 Janus kinase and microtubule-interacting protein 2 Proteins 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
• GAAKALASJNGQKD-UHFFFAOYSA-N LY-165163 Chemical compound C1=CC(N)=CC=C1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 GAAKALASJNGQKD-UHFFFAOYSA-N 0.000 description 1
• WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
• XBBKIIGCUMBKCO-JXUBOQSCSA-N Leu-Ala-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XBBKIIGCUMBKCO-JXUBOQSCSA-N 0.000 description 1
• STAVRDQLZOTNKJ-RHYQMDGZSA-N Leu-Arg-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STAVRDQLZOTNKJ-RHYQMDGZSA-N 0.000 description 1
• IGUOAYLTQJLPPD-DCAQKATOSA-N Leu-Asn-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IGUOAYLTQJLPPD-DCAQKATOSA-N 0.000 description 1
• HVJVUYQWFYMGJS-GVXVVHGQSA-N Leu-Glu-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVJVUYQWFYMGJS-GVXVVHGQSA-N 0.000 description 1
• VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 1
• OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 1
• DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 1
• WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 description 1
• ARNIBBOXIAWUOP-MGHWNKPDSA-N Leu-Tyr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ARNIBBOXIAWUOP-MGHWNKPDSA-N 0.000 description 1
• XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 1
• LMDVGHQPPPLYAR-IHRRRGAJSA-N Leu-Val-His Chemical compound N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O LMDVGHQPPPLYAR-IHRRRGAJSA-N 0.000 description 1
• GJJQCBVRWDGLMQ-GUBZILKMSA-N Lys-Glu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O GJJQCBVRWDGLMQ-GUBZILKMSA-N 0.000 description 1
• PAMDBWYMLWOELY-SDDRHHMPSA-N Lys-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O PAMDBWYMLWOELY-SDDRHHMPSA-N 0.000 description 1
• KEPWSUPUFAPBRF-DKIMLUQUSA-N Lys-Ile-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KEPWSUPUFAPBRF-DKIMLUQUSA-N 0.000 description 1
• VMTYLUGCXIEDMV-QWRGUYRKSA-N Lys-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN VMTYLUGCXIEDMV-QWRGUYRKSA-N 0.000 description 1
• ORVFEGYUJITPGI-IHRRRGAJSA-N Lys-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN ORVFEGYUJITPGI-IHRRRGAJSA-N 0.000 description 1
• OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
• MEQLGHAMAUPOSJ-DCAQKATOSA-N Lys-Ser-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O MEQLGHAMAUPOSJ-DCAQKATOSA-N 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 206010026659 Malignant oligodendroglioma Diseases 0.000 description 1
• 244000141359 Malus pumila Species 0.000 description 1
• 229920000057 Mannan Polymers 0.000 description 1
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
• FVKRQMQQFGBXHV-QXEWZRGKSA-N Met-Asp-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FVKRQMQQFGBXHV-QXEWZRGKSA-N 0.000 description 1
• UNPGTBHYKJOCCZ-DCAQKATOSA-N Met-Lys-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O UNPGTBHYKJOCCZ-DCAQKATOSA-N 0.000 description 1
• 240000002769 Morchella esculenta Species 0.000 description 1
• 235000002779 Morchella esculenta Nutrition 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 description 1
• YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
• SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
• VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
• 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
• 102000004722 NADPH Oxidases Human genes 0.000 description 1
• 108010002998 NADPH Oxidases Proteins 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 1
• 101100117569 Oryza sativa subsp. japonica DRB6 gene Proteins 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• PEFJUUYFEGBXFA-BZSNNMDCSA-N Phe-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 PEFJUUYFEGBXFA-BZSNNMDCSA-N 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 206010034972 Photosensitivity reaction Diseases 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 102000004257 Potassium Channel Human genes 0.000 description 1
• SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 description 1
• NAIPAPCKKRCMBL-JYJNAYRXSA-N Pro-Pro-Phe Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NCCC1)C1=CC=CC=C1 NAIPAPCKKRCMBL-JYJNAYRXSA-N 0.000 description 1
• OQSGBXGNAFQGGS-CYDGBPFRSA-N Pro-Val-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OQSGBXGNAFQGGS-CYDGBPFRSA-N 0.000 description 1
• 230000004570 RNA-binding Effects 0.000 description 1
• 108010025216 RVF peptide Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
• 102100025541 S-acyl fatty acid synthase thioesterase, medium chain Human genes 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• NLQUOHDCLSFABG-GUBZILKMSA-N Ser-Arg-Arg Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NLQUOHDCLSFABG-GUBZILKMSA-N 0.000 description 1
• NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 1
• UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
• VZQRNAYURWAEFE-KKUMJFAQSA-N Ser-Leu-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VZQRNAYURWAEFE-KKUMJFAQSA-N 0.000 description 1
• GVIGVIOEYBOTCB-XIRDDKMYSA-N Ser-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC(C)C)C(O)=O)=CNC2=C1 GVIGVIOEYBOTCB-XIRDDKMYSA-N 0.000 description 1
• VIIJCAQMJBHSJH-FXQIFTODSA-N Ser-Met-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O VIIJCAQMJBHSJH-FXQIFTODSA-N 0.000 description 1
• CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 1
• PCMZJFMUYWIERL-ZKWXMUAHSA-N Ser-Val-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMZJFMUYWIERL-ZKWXMUAHSA-N 0.000 description 1
• 241000212342 Sium Species 0.000 description 1
• 206010040799 Skin atrophy Diseases 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 230000020385 T cell costimulation Effects 0.000 description 1
• 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
• 241001080024 Telles Species 0.000 description 1
• NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 1
• JMZKMSTYXHFYAK-VEVYYDQMSA-N Thr-Arg-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O JMZKMSTYXHFYAK-VEVYYDQMSA-N 0.000 description 1
• FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 1
• MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
• BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 102000008236 Toll-Like Receptor 7 Human genes 0.000 description 1
• 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
• 102000008208 Toll-Like Receptor 8 Human genes 0.000 description 1
• 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 1
• 101150107801 Top2a gene Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• UATJOMSPNYCXIX-UHFFFAOYSA-N Trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UATJOMSPNYCXIX-UHFFFAOYSA-N 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• JRXKIVGWMMIIOF-YDHLFZDLSA-N Tyr-Asn-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JRXKIVGWMMIIOF-YDHLFZDLSA-N 0.000 description 1
• QHLIUFUEUDFAOT-MGHWNKPDSA-N Tyr-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QHLIUFUEUDFAOT-MGHWNKPDSA-N 0.000 description 1
• PRONOHBTMLNXCZ-BZSNNMDCSA-N Tyr-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PRONOHBTMLNXCZ-BZSNNMDCSA-N 0.000 description 1
• 102000003425 Tyrosinase Human genes 0.000 description 1
• 108060008724 Tyrosinase Proteins 0.000 description 1
• 101710098414 Tyrosine-protein phosphatase Proteins 0.000 description 1
• 208000006593 Urologic Neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 1
• JAKHAONCJJZVHT-DCAQKATOSA-N Val-Lys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N JAKHAONCJJZVHT-DCAQKATOSA-N 0.000 description 1
• NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
• LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
• JXCOEPXCBVCTRD-JYJNAYRXSA-N Val-Tyr-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N JXCOEPXCBVCTRD-JYJNAYRXSA-N 0.000 description 1
• AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
• SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 108020005202 Viral DNA Proteins 0.000 description 1
• 108020000999 Viral RNA Proteins 0.000 description 1
• GVBNSPFBYXGREE-CXWAGAITSA-N Visnadin Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)[C@H](C)CC)C(C)(C)O1 GVBNSPFBYXGREE-CXWAGAITSA-N 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 244000126002 Ziziphus vulgaris Species 0.000 description 1
• 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
• RQQIRMLGKSPXSE-WIPMOJCBSA-N [1-acetyloxy-2-[[(2s,3r,5s,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxyethyl] acetate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-WIPMOJCBSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 238000010306 acid treatment Methods 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 108010005233 alanylglutamic acid Proteins 0.000 description 1
• 108010087924 alanylproline Proteins 0.000 description 1
• 229940060265 aldara Drugs 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 159000000013 aluminium salts Chemical class 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000025164 anoikis Effects 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000009949 anti-apoptotic pathway Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000003510 anti-fibrotic effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 230000008349 antigen-specific humoral response Effects 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 210000000436 anus Anatomy 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
• 108010093581 aspartyl-proline Proteins 0.000 description 1
• 238000012550 audit Methods 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 238000010804 cDNA synthesis Methods 0.000 description 1
• 235000020964 calcitriol Nutrition 0.000 description 1
• 239000011612 calcitriol Substances 0.000 description 1
• GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 238000005251 capillar electrophoresis Methods 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 229920006317 cationic polymer Polymers 0.000 description 1
• 229960002412 cediranib Drugs 0.000 description 1
• 229940047495 celebrex Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 210000005056 cell body Anatomy 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 238000009172 cell transfer therapy Methods 0.000 description 1
• 229940030156 cell vaccine Drugs 0.000 description 1
• 210000002421 cell wall Anatomy 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000002230 centromere Anatomy 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 230000006328 chemical modification of amino acids Effects 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
• 210000001612 chondrocyte Anatomy 0.000 description 1
• 210000004756 chromatid Anatomy 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229960005188 collagen Drugs 0.000 description 1
• 229940096422 collagen type i Drugs 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 238000011220 combination immunotherapy Methods 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000011254 conventional chemotherapy Methods 0.000 description 1
• 229910001431 copper ion Inorganic materials 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 208000030381 cutaneous melanoma Diseases 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000004041 dendritic cell maturation Effects 0.000 description 1
• 229940029030 dendritic cell vaccine Drugs 0.000 description 1
• 108010017271 denileukin diftitox Proteins 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 125000004386 diacrylate group Chemical group 0.000 description 1
• 150000004985 diamines Chemical class 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• 125000004989 dicarbonyl group Chemical group 0.000 description 1
• FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• 229960002986 dinoprostone Drugs 0.000 description 1
• 108010054813 diprotin B Proteins 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 229940056913 eftilagimod alfa Drugs 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000001437 electrospray ionisation time-of-flight quadrupole detection Methods 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
• 230000008620 endothelial cell matrix interaction Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 238000010265 fast atom bombardment Methods 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 210000001650 focal adhesion Anatomy 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 230000000477 gelanolytic effect Effects 0.000 description 1
• 238000003500 gene array Methods 0.000 description 1
• 230000004545 gene duplication Effects 0.000 description 1
• 238000003197 gene knockdown Methods 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 108010049041 glutamylalanine Proteins 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 230000036252 glycation Effects 0.000 description 1
• 108010075431 glycyl-alanyl-phenylalanine Proteins 0.000 description 1
• 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
• 230000036449 good health Effects 0.000 description 1
• 210000000020 growth cone Anatomy 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 230000023597 hemostasis Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 230000002102 hyperpolarization Effects 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 229960002751 imiquimod Drugs 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000001571 immunoadjuvant effect Effects 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 239000013038 irreversible inhibitor Substances 0.000 description 1
• JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 238000003475 lamination Methods 0.000 description 1
• 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
• 108010030617 leucyl-phenylalanyl-valine Proteins 0.000 description 1
• 239000002960 lipid emulsion Substances 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 208000022080 low-grade astrocytoma Diseases 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
• 108010017391 lysylvaline Proteins 0.000 description 1
• 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
• 210000005001 male reproductive tract Anatomy 0.000 description 1
• 208000030883 malignant astrocytoma Diseases 0.000 description 1
• 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 230000012241 membrane hyperpolarization Effects 0.000 description 1
• 238000010197 meta-analysis Methods 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
• ZCQGVFNHUATAJY-UHFFFAOYSA-N methyl 2-[methyl(prop-2-enoyl)amino]acetate Chemical compound COC(=O)CN(C)C(=O)C=C ZCQGVFNHUATAJY-UHFFFAOYSA-N 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 235000019837 monoammonium phosphate Nutrition 0.000 description 1
• 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
• NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
• 239000004570 mortar (masonry) Substances 0.000 description 1
• 210000003550 mucous cell Anatomy 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 230000001400 myeloablative effect Effects 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000003988 neural development Effects 0.000 description 1
• 230000007372 neural signaling Effects 0.000 description 1
• 230000002232 neuromuscular Effects 0.000 description 1
• 230000008587 neuronal excitability Effects 0.000 description 1
• 230000007514 neuronal growth Effects 0.000 description 1
• FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
• 201000008585 noma Diseases 0.000 description 1
• 238000009828 non-uniform distribution Methods 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 230000009701 normal cell proliferation Effects 0.000 description 1
• 230000037311 normal skin Effects 0.000 description 1
• 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 230000000269 nucleophilic effect Effects 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 102000027450 oncoproteins Human genes 0.000 description 1
• 108091008819 oncoproteins Proteins 0.000 description 1
• 229940100027 ontak Drugs 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000005305 organ development Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000006174 pH buffer Substances 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 210000004923 pancreatic tissue Anatomy 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229960000639 pazopanib Drugs 0.000 description 1
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 235000020030 perry Nutrition 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 230000036211 photosensitivity Effects 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
• 108020001213 potassium channel Proteins 0.000 description 1
• GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 108010029020 prolylglycine Proteins 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 229940021993 prophylactic vaccine Drugs 0.000 description 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000016434 protein splicing Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 239000000941 radioactive substance Substances 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 238000005932 reductive alkylation reaction Methods 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 201000010174 renal carcinoma Diseases 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 229960003310 sildenafil Drugs 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 229940074386 skatole Drugs 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000006104 solid solution Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000011301 standard therapy Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 108010026810 superoxide-forming enzyme Proteins 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229960000835 tadalafil Drugs 0.000 description 1
• IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 229940021747 therapeutic vaccine Drugs 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
• 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
• 229960002381 vardenafil Drugs 0.000 description 1
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
• 230000004862 vasculogenesis Effects 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 239000000277 virosome Substances 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 108010027345 wheylin-1 peptide Proteins 0.000 description 1
• 239000012224 working solution Substances 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1